---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084251"
form_type: "8-K"
ticker: "DBVT"
cik: "0001613780"
company_name: "DBV Technologies S.A."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:39:56.493454+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# DBV Technologies reports additional positive Phase 3 VITESSE data for VIASKIN Peanut Patch at AAAAI 2026

## Summary
- 82.8% of treated children increased eliciting dose at month 12 vs ~48% placebo; 60.1% increased by ≥2 doses vs 23.4% placebo.
- 24% of placebo group decreased eliciting dose over 12 months vs 6.4% of treated group, indicating reduced sensitization.
- VIASKIN Peanut Patch was well tolerated; most adverse events were mild local application site reactions.
- Company plans to submit Biologics License Application (BLA) to FDA in the first half of 2026.
- All sensitivity analyses significant; response rate difference exceeded prespecified 15% threshold.

## SEC filing metadata
- accession: 0001193125-26-084251
- form_type: 8-K
- ticker: DBVT
- cik: 0001613780
- company_name: DBV Technologies S.A.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613780/000119312526084251/0001193125-26-084251-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613780/000119312526084251/d110966d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084251
- JSON: https://secwatch.observer/filing/0001193125-26-084251.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084251.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.